The people behind the work.

Co-founder and CEO.

Fernando Garces, PhD, CEO and Co-founder of NovoFy, is a biotech entrepreneur and protein engineering expert with 20+ years of experience spanning academia, biopharma, and AI-driven drug discovery.

He earned his PhD in Biotechnology from the University of Barcelona and conducted postdoctoral research at the Institute of Cancer Research and The Scripps Research Institute, where he focused on oncology targets and structure-guided protein design for HIV-1 vaccines. He subsequently held scientific and leadership roles at Amgen, Gilead, and BioMap, advancing next-generation biologics and computational protein design.

Fernando previously founded and led BioGlyph, securing strategic partnerships with Gilead and Johnson & Johnson, and now leads NovoFy, where he is building AI-powered technologies for scalable protein design. He is an inventor on 20+ patents, author of 35+ peer-reviewed publications, and recipient of the Scripps CHAVI-ID Young Investigator Award.

Co-founder and CTO. NovoFlow lead.

Daniel holds a PhD in Biotechnology and Bioengineering from EPFL and brings more than 10 years of experience at the intersection of protein engineering, computational design, and wet-lab validation. He has led multidisciplinary programs spanning protein discovery, engineering, optimization, and developability across multiple biologic modalities, with scientific and technical roles at Gilead Sciences and BioGlyph.

His expertise includes challenging protein targets and engineered biologics, with a particular focus on GPCRs, multispecific antibodies, and other complex protein modalities. During his doctoral research, Daniel studied hard-to-target GPCRs, developing expertise in protein structure, molecular recognition, and engineering.

At NovoFy, Daniel leads the development of NovoFlow, integrating ML-based models with physics-based approaches to design novel, bespoke protein binders.

Scientific Advisory Board. Director of Engineering, Google DeepMind.

Vitor Rodrigues is Director of Engineering at Google DeepMind, leading the Gemini Deployment and Inference Performance organizations, driving the research-to-production model serving lifecycle and fleet-wide efficiency initiatives.

With two decades of Silicon Valley experience building large-scale ML infrastructure, Vitor has also dedicated several years to applying AI/ML in healthcare (Google and Curai Health).

He brings deep expertise in technical strategy, engineering leadership, and scaling AI innovation to early-stage founders, with a particular focus on Life Sciences.

Scientific Advisory Board. Chief Scientific Officer, Equillium.

Steve has spent 20+ years in the life sciences as an academic, investor and operator. He is Chief Scientific Officer of Equillium, Inc, which he co-founded in 2017 and where he serves on the board of directors. He has helped build Equillium to over 60 employees, advancing multiple novel drugs from discovery into late-stage clinical development, and has led licensing deals, M&A, and over $200M in private and public financings, including an IPO in 2018.

Earlier, Steve was a Principal at BioMed Ventures and Director of Business Development and Therapeutic Alliances at aTyr. As a Senior Scientist at The Scripps Research Institute, he worked on the discovery and development of the ATTR stabilizers Tafamidis (Vyndaqel®, Vyndamax®) and Acoramidis (Attruby®).

Steve holds a BSc in Medicinal Chemistry and a PhD in Biological Chemistry from the University of Exeter, and an MBA from the Rady School at UC San Diego.

Coming soon

Commercial advisor

Advisory Board.

We will announce our commercial advisor soon.